$HYPR
Hyperfine, Inc.

2023 Q1 Form 10-Q Financial Statement

#000095017023021378 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q1
Revenue $2.635M $1.509M
YoY Change 74.62% 355.89%
Cost Of Revenue $1.480M $1.425M
YoY Change 3.86% 134.38%
Gross Profit $1.155M $84.00K
YoY Change 1275.0% -130.32%
Gross Profit Margin 43.83% 5.57%
Selling, General & Admin $8.729M $15.52M
YoY Change -43.76% 408.22%
% of Gross Profit 755.76% 18477.38%
Research & Development $5.461M $8.334M
YoY Change -34.47% 86.28%
% of Gross Profit 472.81% 9921.43%
Depreciation & Amortization $254.0K $253.0K
YoY Change 0.4% 163.54%
% of Gross Profit 21.99% 301.19%
Operating Expenses $14.19M $23.86M
YoY Change -40.52% 216.88%
Operating Profit -$13.04M -$23.77M
YoY Change -45.16% 204.56%
Interest Expense $869.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $6.000K -$5.000K
YoY Change -220.0% -183.33%
Pretax Income -$12.16M -$23.78M
YoY Change -48.85% 205.04%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.16M -$23.78M
YoY Change -48.85% 205.04%
Net Earnings / Revenue -461.48% -1575.55%
Basic Earnings Per Share -$0.17 -$0.34
Diluted Earnings Per Share -$0.17 -$0.34
COMMON SHARES
Basic Shares Outstanding 70.86M 70.33M
Diluted Shares Outstanding 70.86M 70.33M

Balance Sheet

Concept 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $104.0M
YoY Change
Cash & Equivalents $104.0M $161.6M
Short-Term Investments
Other Short-Term Assets $3.636M
YoY Change
Inventory $5.744M $4.538M
Prepaid Expenses
Receivables $3.018M $1.944M
Other Receivables $713.0K
Total Short-Term Assets $117.1M $173.7M
YoY Change -32.57% 11910.13%
LONG-TERM ASSETS
Property, Plant & Equipment $3.091M $3.877M
YoY Change -20.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.873M $1.222M
YoY Change 53.27%
Total Long-Term Assets $4.964M $5.099M
YoY Change -2.65% -97.54%
TOTAL ASSETS
Total Short-Term Assets $117.1M $173.7M
Total Long-Term Assets $4.964M $5.099M
Total Assets $122.1M $178.8M
YoY Change -31.72% -14.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.668M $1.745M
YoY Change -4.41%
Accrued Expenses $4.141M
YoY Change
Deferred Revenue $1.415M $973.0K
YoY Change 45.43%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.001M $11.41M
YoY Change -29.9% 9132.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $1.364M
YoY Change
Total Long-Term Liabilities $1.364M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.001M $11.41M
Total Long-Term Liabilities $1.364M
Total Liabilities $9.365M $12.27M
YoY Change -23.64% 66.45%
SHAREHOLDERS EQUITY
Retained Earnings -$221.6M -$160.1M
YoY Change 38.45% 2605.11%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $112.7M $166.6M
YoY Change
Total Liabilities & Shareholders Equity $122.1M $178.8M
YoY Change -31.72% -14.21%

Cashflow Statement

Concept 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$12.16M -$23.78M
YoY Change -48.85% 205.04%
Depreciation, Depletion And Amortization $254.0K $253.0K
YoY Change 0.4% 163.54%
Cash From Operating Activities -$13.49M -$27.29M
YoY Change -50.56% 264.53%
INVESTING ACTIVITIES
Capital Expenditures $61.00K $308.0K
YoY Change -80.19% 81.18%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$61.00K -$308.0K
YoY Change -80.19% 81.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 49.00K
YoY Change
NET CHANGE
Cash From Operating Activities -13.49M -27.29M
Cash From Investing Activities -61.00K -308.0K
Cash From Financing Activities 49.00K
Net Change In Cash -13.50M -27.60M
YoY Change -51.07% -3279.37%
FREE CASH FLOW
Cash From Operating Activities -$13.49M -$27.29M
Capital Expenditures $61.00K $308.0K
Free Cash Flow -$13.55M -$27.60M
YoY Change -50.89% 260.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001833769
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39949
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Hyperfine, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1569027
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
351 New Whitfield Street
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Guilford
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06437
CY2023Q1 dei City Area Code
CityAreaCode
866
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
-6767
CY2023Q1 dei Security12b Title
Security12bTitle
Class A common stock, $0.0001 Par Value Per Share
CY2023Q1 dei Trading Symbol
TradingSymbol
HYPR
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
678000
CY2023Q1 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
713000
CY2022Q4 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
771000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1415000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1378000
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
64000
CY2023Q1 hypr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
4141000
CY2022Q4 hypr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5976000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8001000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8803000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1364000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1526000
CY2023Q1 us-gaap Liabilities
Liabilities
9365000
CY2022Q4 us-gaap Liabilities
Liabilities
10329000
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104027000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117472000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
713000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
771000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
191000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
180000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3018000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2103000
CY2023Q1 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
713000
CY2022Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
454000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
334374000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
333199000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-221644000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-209484000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
112737000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
123722000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
122102000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
134051000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2635000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1509000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1480000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1425000
CY2023Q1 us-gaap Gross Profit
GrossProfit
1155000
CY2022Q1 us-gaap Gross Profit
GrossProfit
84000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5461000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8334000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6182000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11360000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2547000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4161000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
14190000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
23855000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13035000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-23771000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
869000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12160000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23775000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-12160000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23775000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q1 us-gaap Inventory Net
InventoryNet
5744000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4622000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2923000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3194000
CY2022Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
48000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
117138000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
128664000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3091000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3248000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1873000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2139000
CY2023Q1 us-gaap Assets
Assets
122102000
CY2022Q4 us-gaap Assets
Assets
134051000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1668000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70864226
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70864226
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70332349
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70332349
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
123722000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-12160000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
49000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1126000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
112737000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186227000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23775000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4111000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
166563000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-12160000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-23775000
CY2023Q1 us-gaap Depreciation
Depreciation
254000
CY2022Q1 us-gaap Depreciation
Depreciation
253000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1126000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4111000
CY2023Q1 us-gaap Net Investment In Lease Purchase
NetInvestmentInLeasePurchase
2000
CY2022Q1 us-gaap Net Investment In Lease Purchase
NetInvestmentInLeasePurchase
2000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
915000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1391000
CY2023Q1 hypr Unbilled Receivables
UnbilledReceivables
259000
CY2022Q1 hypr Unbilled Receivables
UnbilledReceivables
387000
CY2023Q1 hypr Revenue Remaining Performance Obligation Expected Timing Percentage
RevenueRemainingPerformanceObligationExpectedTimingPercentage
0.49
CY2022Q1 us-gaap Depreciation
Depreciation
253000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1122000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
228000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-272000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1848000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-48000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-13000
CY2023Q1 us-gaap Increase Decrease In Prepaid Supplies
IncreaseDecreaseInPrepaidSupplies
-281000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
18000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-11000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
954000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-565000
CY2023Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-58000
CY2022Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-679000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-125000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
584000
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
64000
CY2022Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-1884000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1835000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1506000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13491000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27289000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
61000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
308000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-61000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-308000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
49000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-13503000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-27597000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
118243000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
191160000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104740000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163563000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104027000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
161580000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
713000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1983000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104740000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163563000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
36000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
62000
CY2022Q1 hypr Write Off Of Notes Receivable
WriteOffOfNotesReceivable
90000
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
54211
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
444776
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1364000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1526000
CY2023Q1 hypr Revenue Recognize Receivable Payment Terms Range Minimum
RevenueRecognizeReceivablePaymentTermsRangeMinimum
P30D
CY2023Q1 hypr Revenue Recognize Receivable Payment Terms Range Maximum
RevenueRecognizeReceivablePaymentTermsRangeMaximum
P1Y
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
430000
CY2022Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
203000
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and trade receivables. The Company maintains cash deposits with financial institutions that, from time to time, exceed applicable insurance limits. The Company reduces this risk by maintaining such deposits with high quality financial institutions that management believes are creditworthy. Cash and cash equivalents are maintained with several financial institutions domestically and internationally. The combined account balances held on deposit at each institution typically exceed Federal Deposit Insurance Corporation (“FDIC”) insurance coverage and, as a result, there is a concentration of credit risk related to amounts on deposit in excess of FDIC insurance coverage. The Company monitors this credit risk and makes adjustments to the concentrations as necessary. As of March 31, 2023 and December 31, 2022, the Company had total cash deposits and cash equivalents of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93,648</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92,732</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. Total cash deposits exceeded the FDIC insurance coverage amounts.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to accounts receivable, credit risk is mitigated by the Company’s ongoing credit evaluation of its customers’ financial condition. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> customers accounted for more than 10 percent of trade receivables for the three months ended March 31, 2023 and the years ended December 31, 2022. With respect to revenues, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> customer accounted for more than 10% of revenues for the three months ended March 31, 2023 and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> customers each accounted for more than 10% of revenue for the three months ended March 31, 2022.</span></p>
CY2023Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
93648000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
92732000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions about future events that affect the amounts reported in its condensed consolidated financial statements and accompanying notes. Future events and their effects cannot be determined with certainty. On an ongoing basis, management evaluates these estimates and assumptions. Significant estimates and assumptions included:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue recognition, including determination of the timing and pattern of satisfaction of performance obligations, determination of the standalone selling price (“SSP”) of performance obligations and estimation of variable consideration, if any;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Allowance for credit losses;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net realizable value (the selling price as well as estimated costs of disposal and transportation) of inventory, and demand and future use of inventory;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowances with respect to deferred tax assets; and</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assumptions underlying the fair value used in the calculation of stock-based compensation expense.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company bases these estimates on historical and anticipated results and trends and on various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates, and any such differences may be material to the Company’s condensed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">consolidated financial statements.</span></p>
CY2023Q1 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
180000
CY2022Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
247000
CY2023Q1 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
16000
CY2022Q1 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
84000
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
8675000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2635000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1509000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3018000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2103000
CY2023Q1 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
713000
CY2022Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
454000
CY2023Q1 hypr Unbilled Receivables Noncurrent
UnbilledReceivablesNoncurrent
781000
CY2022Q4 hypr Unbilled Receivables Noncurrent
UnbilledReceivablesNoncurrent
744000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1415000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1378000
CY2022Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
8663000
CY2023Q1 hypr Revenue Remaining Performance Obligation Expected Timing Percentage
RevenueRemainingPerformanceObligationExpectedTimingPercentage
0.51
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13297988
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2023Q1 hypr Fair Value Assets Transfer Between Levels Amount
FairValueAssetsTransferBetweenLevelsAmount
0
CY2022Q1 hypr Fair Value Assets Transfer Between Levels Amount
FairValueAssetsTransferBetweenLevelsAmount
0
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2552000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2241000
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3192000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2381000
CY2023Q1 us-gaap Inventory Net
InventoryNet
5744000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4622000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5667000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5570000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2576000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2322000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3091000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3248000
CY2023Q1 us-gaap Depreciation
Depreciation
254000
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2023Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1061000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2674000
CY2023Q1 hypr Accrued Contracted Services Current
AccruedContractedServicesCurrent
837000
CY2022Q4 hypr Accrued Contracted Services Current
AccruedContractedServicesCurrent
1127000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
263000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
261000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1648000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1876000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
332000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38000
CY2023Q1 hypr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
4141000
CY2022Q4 hypr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5976000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10719564
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3077411
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1126000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4111000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-12160000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23775000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12160000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23775000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70864226
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70864226
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70332349
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70332349
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23850200
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23260512
CY2018Q1 us-gaap Due From Employees Noncurrent
DueFromEmployeesNoncurrent
90000
CY2018Q1 us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.0168
CY2022Q1 hypr Due From Employees Forgiveness
DueFromEmployeesForgiveness
90000
CY2020Q4 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
1610000
CY2020 hypr Number Of Sites
NumberOfSites
20
CY2021 hypr Grant Awarded
GrantAwarded
3300000
CY2021 hypr Grant Awarded For Provision And Equipping
GrantAwardedForProvisionAndEquipping
2500000
CY2021 hypr Number Of Sites
NumberOfSites
5
CY2023Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-58000
CY2023Q1 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
713000
CY2022Q4 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
771000
CY2023Q1 hypr Grant Fund Required To Return Under Provisions
GrantFundRequiredToReturnUnderProvisions
0
CY2022Q4 hypr Grant Fund Required To Return Under Provisions
GrantFundRequiredToReturnUnderProvisions
0
CY2023Q1 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
2225
CY2023Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P12M
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
129000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
65000
CY2022 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
1000000
CY2023Q1 hypr Earn Out Liability
EarnOutLiability
0
CY2023Q1 hypr Restructuring And Related Expenses
RestructuringAndRelatedExpenses
1016000

Files In Submission

Name View Source Status
0000950170-23-021378-index-headers.html Edgar Link pending
0000950170-23-021378-index.html Edgar Link pending
0000950170-23-021378.txt Edgar Link pending
0000950170-23-021378-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hypr-20230331.htm Edgar Link pending
hypr-20230331.xsd Edgar Link pending
hypr-ex10_5.htm Edgar Link pending
hypr-ex31_1.htm Edgar Link pending
hypr-ex31_2.htm Edgar Link pending
hypr-ex32.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
hypr-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
hypr-20230331_def.xml Edgar Link unprocessable
hypr-20230331_lab.xml Edgar Link unprocessable
hypr-20230331_pre.xml Edgar Link unprocessable
hypr-20230331_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending